Home > Healthcare > Drug Device Combination > Therapeutic Systems > Radiotherapy Induced Oral Mucositis Treatment Market
Radiotherapy Induced Oral Mucositis Treatment Market size was valued at around USD 2.5 billion in 2023 and is estimated to grow at 4.4% CAGR from 2024 to 2032, driven by the increasing incidence of cancer necessitating radiotherapy coupled with advancements in radiotherapy techniques and a growing focus on supportive care.
According to the latest estimates from the International Agency for Research on Cancer (IARC) in 2022, there were approximately 20 million new cancer cases projecting a rise of over 35 million new cancer cases that by 2050, reflecting a substantial 77% increase from the estimated cases in 2022. Therefore, the increasing prevalence of cancer elevates the demand for cancer treatments such as radiotherapy, consequently boosting the need for remedies targeting oral mucositis and propelling market expansion.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Radiotherapy Induced Oral Mucositis Treatment Market Size in 2023: | USD 2.5 Billion |
Forecast Period: | 2024 - 2032 |
Forecast Period 2024 - 2032 CAGR: | 4.4% |
2032 Value Projection: | USD 3.7 Billion |
Historical Data for: | 2021 - 2023 |
No. of Pages: | 190 |
Tables, Charts & Figures: | 401 |
Segments covered: | Treatment Type, Severity Type, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Radiotherapy induced oral mucositis treatment refers to therapeutic interventions aimed at managing and alleviating the adverse effects of oral mucositis induced by radiotherapy. This condition characterized by inflammation, ulceration, and pain in the oral mucosa, commonly occurs as a side effect of radiation therapy for head and neck cancer or other types of cancers.